Report Analysis and Forecast on Osteoarthritis - Pipeline Review, H2 2016

Osteoarthritis - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

To view the table of contents and know more details please visit Osteoarthritis - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
- The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Abiogen Pharma S.p.A. Ablynx NV Achelios Therapeutics, Inc. Addex Therapeutics Ltd Amgen Inc. Amura Holdings Limited Arcarios BV Asahi Kasei Pharma Corp. Asklepios BioPharmaceutical, Inc. Astellas Pharma Inc. Asterias Biotherapeutics, Inc. Biopharm GmbH Bone Therapeutics SA Can-Fite BioPharma Ltd. Cardax Pharmaceuticals, Inc. Cellceutix Corporation Cellular Biomedicine Group, Inc. Evgen Pharma Plc Galapagos NV Genequine Biotherapeutics GmbH GlaxoSmithKline Plc IntelliCell BioSciences Inc. Jeil Pharmaceutical Co., Ltd. Jenrin Discovery, Inc. K-Stemcell Co., Ltd. Levolta Pharmaceuticals, Inc. Medivir AB Merck KGaA Mesoblast Limited Mor Research Application Ltd NicOx S.A. Nordic Bioscience A/S Novartis AG Omeros Corporation Ono Pharmaceutical Co., Ltd. OrthoCyte Corporation Osteologix Holdings Plc. Pfizer Inc. Pharmalink AB Philogen S.p.A. PLx Pharma Inc. ProteoThera, Inc. Regeneus Ltd Seikagaku Corporation STELIS Biopharma Pvt. Ltd. Symic Biomedical, Inc. Takeda Pharmaceutical Company Limited TissueGene, Inc. Upsher-Smith Laboratories, Inc. Yooyoung Pharmaceutical Co., Ltd. Yuhan Corporation Yungjin Pharm. Co., Ltd. Zimmer Biomet Holdings, Inc. Zynerba Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###